

Ref No. GIL/CFD/SEC/26/018/SE

15<sup>th</sup> May 2025

BSE Limited National Stock Exchange of India Limited Scrip Code: 500300 Symbol: GRASIM

**Sub: Monitoring Agency Report** 

Ref: Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015

Regulation 82(4) of the SEBI (Issue of Capital and Disclosure Requirements)

Regulations, 2018

Dear Sirs,

Please find enclosed Monitoring Agency Report for the quarter ended 31<sup>st</sup> March 2025, issued by CARE Ratings Limited for utilisation of funds of Rights Issue of the Company. There is no variation / deviation in the utilisation of such funds.

The aforesaid information is also being made available on the website of the Company at www.grasim.com

Thanking you,

Yours sincerely,
For Grasim Industries Limited

Sailesh Kumar Daga Company Secretary and Compliance Officer FCS - 4164

Encl: As above

Cc:

Luxembourg Stock Exchange 35A Boulevard Joseph II L-1840 Luxembourg Citibank N.A.

Depositary Receipt Services
390 Greenwich Street,
4th Floor, New York,
NY 10013

Citibank N.A.
Custodial Services
FIFC, 9<sup>th</sup> Floor, C-54 &
55,G Block Bandra Kurla
Complex, Bandra (East),
Mumbai - 400098

Regd. Office: P.O. Birlagram, Nagda - 456 331 (M.P.)



## **Monitoring Agency Report**

No. CARE/HO/GEN/2025-26/1036

The Board of Directors Grasim Industries Limited P.O. Birlagram, Nagda – 456331 (M.P.)

May 15, 2025

Dear Sir/Ma'am,

# Monitoring Agency Report for the quarter ended March 31, 2025 - in relation to the Rights issue of Grasim Industries Limited ("the Company")

We write in our capacity of Monitoring Agency for the Rights Issue for the amount aggregating to Rs. 3,999.80 crore of the Company and refer to our duties cast under 82 of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended March 31, 2025, as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated January 04, 2024.

Request you to kindly take the same on records.

Thanking you,

Yours faithfully,

**Arti Roy** 

**Associate Director** 

arti.roy@careedge.in



#### **Report of the Monitoring Agency**

Name of the issuer: Grasim Industries Ltd For quarter ended: March 31, 2025

Name of the Monitoring Agency: CARE Ratings Limited

(a) Deviation from the objects: Nil(b) Range of Deviation: Not Applicable

#### **Declaration:**

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature:

Name and designation of the Authorized Signatory: Arti Roy

Designation of Authorized person/Signing Authority: Associate Director



#### 1) Issuer Details:

Name of the issuer : Grasim Industries Ltd

Name of the promoter : Kumar Mangalam Birla, Neerja Birla, Rajashree Birla, Vasavadatta Bajaj, Aditya Vikram Kumarmangalam Birla HUF,

Ananyashree Birla, Aryaman Vikram Birla, Advaitesha Birla, Birla Consultants Ltd, Birla Industrial Finance (India) Ltd, Birla Industrial Investments (India) Ltd, Hindalco Industries Ltd, Birla Group Holdings Pvt Ltd, Rajratna Holdings Pvt Ltd, Vikram Holdings Pvt Ltd, Vaibhav Holdings Pvt Ltd, Birla Institute Of Technology And Science, Pilani Investment And Industries, Renuka Investments & Finance Ltd, IGH Holdings Pvt Ltd, Ece Industries Ltd, P.T. Indo Bharat Rayon, P T Sunrise Bumi Textiles, P T Elegant Textile Industry, Thai Rayon Public Company Ltd, Surva Kiran Investments Pte Ltd & Anatole Investments Pte Ltd.

Industry/sector to which it belongs : Producer of Cellulose, caustic soda, speciality chemicals, rayon-grade wood pulp, linen yarn, fabrics, paints, cement,

financials services, renewables and B2B online marketplace for building materials.

#### 2) Issue Details

Issue Period : January 17, 2024 to January 29, 2024

Type of issue (public/rights) : Rights

Type of specified securities : Equity Shares IPO Grading, if any : Not Applicable

Issue size (in crore) : Rs. 3,999.80 crore (Note 1)

#### Note 1:

The company had offered 2,20,73,935 Equity Shares under the rights issue, at Rs.1,812 per share (including share premium of Rs.1,810 per share) aggregating to ₹ 3,999.80 crore. The issue was Subscribed by 1.97 times; however, 3,025 shares are kept in abeyance pending regulatory/other clearances. The company has allotted 2,20,70,910 Equity Shares to the applicants aggregating to Rs.3,999.25 crore (2,20,70,910 shares X Rs.1,812). Of this, Rs.453 per share (25% of Rs.1,812), including a share premium of Rs.452.50 per share (25% of Rs.1,810), has been received as share application money, another Rs.453 per share (25% of Rs.1,812), including a share premium of Rs.452.50 per share (25% of Rs.1,810), has been received as first call money and balance Rs.906 per share (50% of Rs.1,812), including a share premium of Rs.905 per share (50% of Rs.1,810), has been received as second and final call money. Upon allotment, the company has received Rs.999.81 crore (2,20,70,910 shares X Rs.453) as share application money, Rs.998.37 crore (2,20,39,113 shares X Rs.453) as first call money and Rs.1,993.42 crore (2,20,02,465 shares X Rs.906) as second and final call money. The promoter shareholding prior to Rights issue as on December 31, 2023 was 42.75%. The same now stands at 43.11% as on March 31, 2025 after Rights issue.



### 3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	CA Certificate*	All the proceeds from QIP have been utilized appropriately for the objectives mentioned in the offer document.	No comments
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Offer Document?	Not Applicable	Not Applicable	Not Applicable	Not Applicable
Whether the means of finance for the disclosed objects of the issue have changed?	No	CA Certificate*	No comments	No comments
Is there any major deviation observed over the earlier monitoring agency reports?	No	Earlier monitoring agency report for the quarter ended December 31, 2024	No, there are no deviations observed from the last monitoring agency reports	No comments
Whether all Government/statutory approvals related to the object(s) have been obtained?	Yes	Listing approvals	No comments	No comments
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Not Applicable	Not Applicable	Not Applicable	Not Applicable
Are there any favorable/unfavorable events affecting the viability of these object(s)?	No	CA Certificate*	No comments	No comments
Is there any other relevant information that may materially affect the decision making of the investors?	No	CA Certificate*	No comments	No comments

<sup>\*</sup>Chartered Accountant certificate from Nerkar & Co. (peer reviewed audit firm) vide CA certificate dated May 08, 2025 #Where material deviation may be defined to mean:

- a) Deviation in the objects or purposes for which the funds have been raised
- b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.



# 4) Details of objects to be monitored:

(i) Cost of objects -

		Source of information /	Oviginal cost		Commonto	Comm	mments of the Board of Directors		
Sr N o	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original cost (as per the Offer Document) in Rs. Crore	Revised Cost in Rs. Crore	of the Monitoring Agency	Reason for cost revision	Proposed financing option	Particulars of - firm arrangements made	
1	Repayment or prepayment, in full or in part, of certain borrowings availed by the company	Offer document	3,000.00	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	
2	General corporate purposes	Offer document	977.65	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	
	otal	3,977.65							

(ii) Progress in the objects -

		Source of information / certifications	Amount as	Amount received as proposed	Amount	utilised in Rs	. Crore	Total unutilised amount in Rs. Crore	Comments of the Monitoring Agency	Comments of Dire	
Sr. No	Item Head	considered by Monitoring Agency for preparation of report	proposed in the Offer Document in Rs. Crore	in the Offer Document in Rs. Crore	As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore			Reasons for idle funds	Proposed course of action
1	Repayment or prepayment, in full or in part, of certain	CA Certificate*	3,000.00	3,000.00	1,966.09	1,033.91	3,000.00	-	Company has used issue proceeds for repayment of its term loans.	Not Applicable	Not Applicable

**CARE Ratings Limited** 

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai Phone: +91-22-6754 3456 • www.careedge.in



		Source of information / certifications	Amount received as proposed		Amount	t utilised in Rs.	. Crore	Total unutilised amount in Rs. Crore	Comments of the Monitoring Agency	Comments of Dire	
Sr. No	Item Head	considered by Monitoring Agency for preparation of report	in the Offer Document in Rs. Crore	in the Offer Document in Rs. Crore	As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore			Reasons for idle funds	Proposed course of action
	borrowings availed by the company								Company has repaid total term loan of Rs.1,250 crore out of which Rs.1,033.91 crore is from issue proceeds and balance is out of its own funds.		
2	General corporate purposes	CA Certificate*	977.65	967.26	-	967.26	967.26	-	Use of issue proceeds towards GCP is for repayment of Commercial paper. Company has repaid total CP of Rs.1,000 crore out of which Rs.967.26 crore is from issue proceeds and balance is out of its own funds.	Not Applicable	Not Applicable
Total		1	3,977.65	3,967.26	1,966.09	2,001.17	3,967.26	-			

<sup>\*</sup>The above details are verified by Nerkar & Co. (peer reviewed audit firm) vide CA certificate dated May 08, 2025

Note: Funds have been transferred from company's monitoring account to its current account with HDFC Bank and Cash Credit account of Axis Bank and funds have been utilized for the defined objects from those accounts.

# **CARE Ratings Limited**

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai Phone: +91-22-6754 3456 • www.careedge.in



(iii) Deployment of unutilized proceeds: Nil

Sr.	No.	Type of instrument and name of the entity invested in	Amount invested	Maturity date	Earning	Return on Investment (%)	Market Value as at the end of quarter

(iv) Delay in implementation of the object(s) -

	Completion Date		Delay (no. of	Comments of t	he Board of Directors
Objects	As per the offer document	Actual	days/ months)	Reason of delay	Proposed course of action
Repayment or prepayment, in full or in part, of certain borrowings availed by the company	The company has until March 2026 to raise the remaining funds and can use the net proceeds by March 2027, according to the	On Schedule		Not Applicable	Not Applicable
General corporate purposes	offer document.				

# 5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

Sr. No	Item Head^	Amount in Rs.	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of Monitoring Agency	Comments of the Board of Directors
1	General corporate purposes	967.26	CA Certificate*	Use of issue proceeds towards GCP is for repayment of Commercial paper. Company has repaid total CP of Rs.1,000 crore out of which Rs.967.26 crore is from issue proceeds and balance is out of its own funds.	No comments
	Total	967.26			

<sup>\*</sup>The above details are verified by Nerkar & Co. (peer reviewed audit firm) vide CA certificate dated May 08, 2025

<sup>^</sup> Section from the offer document related to GCP:

<sup>&</sup>quot;Our Company intends to deploy the balance Net Proceeds aggregating up to Rs.977.65 crore towards general corporate purposes, provided that the amount to be utilized for general corporate purposes shall not exceed 25% of the Issue Proceeds, in compliance with the SEBI ICDR Regulations."



#### Note:

Disclosure of Interest of Independent/Non-Executive Directors of CARE:

Name of Director	Designation of Director
V. Chandrasekaran	Non-Executive - Independent Director

Mr. V. Chandrasekaran who is Non-Executive – Independent Director on the Board of Grasim Industries Ltd. is also a Non-Executive – Independent Director of CARE. Independent/Non-executive Directors of CARE are not a part of CARE's Rating Committee and do not participate in the rating process.

# **Disclosure of Interest of Managing Director & CEO:**

Not Applicable



#### **Disclaimers to MA report:**

a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as "Monitoring Agency/MA"). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.

b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditors (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.

c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.

d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.

e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.